Chao  Hu Hu

Dr. Chao Hu Hu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Triple-negative breast cancer (TNBC) is a highly heterogeneous cancer lacking actionable targets. Using a phenotypic screen of TNBC cells, we discovered a novel multiple kinase inhibitor tinengotinib (TT-00420) that strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays. Exposure to tinengotinib specifically inhibited proliferation across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent downregulation of genes essential for TNBC cell growth and proliferation. Studies revealed that the potential mechanism of action of tinengotinib involved, predominantly, inhibition of Aurora A or B kinase activity, while inhibition of other pathways contributed to suppression of potency and activity. In vitro treatment of TNBC cell lines or in vivo administration in a syngeneic model with tinengotinib resulted in up-regulation of CXCL10 and 11 or diminished tumor-associated macrophage (TAM) infiltration. Tinengotinib represents a novel combinatorial inhibitory mechanism to treat TNBC. The phase I trial of tinengotinib was completed (ClinicalTrials.gov identifier: NCT03654547).

7 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
YLYan Luo
Yan Luo
GZGuochen Zhang
Guochen Zhang
CHChao Hu Hu
Chao Hu Hu
LHLijun Huang
Lijun Huang
DWDong Wang
Dong Wang
YWYumei Wang
Yumei Wang
The toll-like receptor 4 (TLR4) signaling pathway constitutes an intricate network of protein interactions primarily involved in inflammation and cancer. This pathway triggers intracellular signaling cascades, modulating transcription factors that regulate gene expression related to immunity and malignancy. Previous studies showed that colon cancer patients with low TLR4 expression exhibit extended survival times and the TLR4 signaling pathway holds a significant role in CRC pathogenesis. In recent years, traditional Chinese medicines (TCMs) have garnered substantial attention as an alternative therapeutic modality for CRC, primarily due to their multifaceted composition and ability to target multiple pathways. Emerging evidence indicates that specific TCM products, such as andrographolide, rosmarinic acid, baicalin, etc., have the potential to impede CRC development through the TLR4 signaling pathway. Here, we review the role and biochemical processes of the TLR4 signaling pathway in CRC, and natural products from TCMs affecting the TLR4 pathway. This review sheds light on potential treatment strategies utilizing natural TLR4 inhibitors for CRC, which contributes to the advancement of research and accelerates their clinical integration into CRC treatment.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib highly inhibits TNBC cell by a panel of specific mechanisms.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
72h-treament of tinengotinib strongly inhibits HUVEC cell viability in a dose-dependent manner.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib indirectly blocks EGFR signaling pathway without affecting PTPN12.